can be functionally promiscuous, capable of maintaining health as well as aggravating immune pathologies [11, 14, 15] .
The recent publication by Muzzio and colleagues at the University of Greifswald in Germany has begun to close the gap in knowledge on the function and modifications of B cell subsets and their function during pregnancy [16] . In their study, the Greifswald group provides evidence that B cell development undergoes significant adaptations over the course of pregnancy in allogeneically mated mice [16] . These adaptations include a gradual reduction in numbers of pre/pro and, to a lesser extent, immature B cells in the bone marrow early during gestation, prior to the completion of placentation. These findings overcome a limitation of previously published evidence, in which a similar suppression of B lymphopoiesis during gestation had also been observed, but cells from different gestational stages had been pooled [17] .
By midgestation, the Greifswald group observed a clear reduction in numbers of B cell precursors together with an increase in numbers of mature B cells, which together suggest an a reduction in B cell lymphopoiesis. Subsequent in-depth analyses of B cell development in the periphery unveiled a preponderance of marginal zone B cells in the spleen. Splenic marginal zone B cells can give rise to antibody-secreting memory B cells and plasma cells, which are required to deal with infections such as the influenza A virus. Hence, it is possible that mechanisms are activated to overcome potential limitations of maternal immunity associated with the observed B cell lymphopoiesis during pregnancy. The effectiveness of such marginal zone B cells will have to be tested in future studies, for example in models of influenza-related morbidity and mortality during pregnancy. The Greifswald group also described a pregnancy-related decrease in serum levels of B cell-activating factor (BAFF), a cytokine that belongs to the tumor necrosis factor superfamily [18] . BAFF is a survival factor for autoreactive B cells, and hence reduced levels of BAFF may account for the reduced occurrence of autoreactive B cells and amelioration of MS during pregnancy [19] . Considering that maternal B cells are the source of antibody-mediated protective immunity for the newborn, insights on regulatory functions of B cells during pregnancy and the early postpartum period may not only be relevant to understand maternal immune adaptation to pregnancy, but also ensure neonatal health by protecting the newborn from infections [20] . In fact, mice lacking functional B cells are able to complete an uncompromised pregnancy, but survival of offspring is severely compromised because of the absent transmission of protective antibodies during the suckling period [21] .
Taken together, the considerable lack of knowledge surrounding the role of B cells during pregnancy and the perinatal period is increasingly addressed in reproductive biology research over the last years [22] [23] [24] and the present work of the Greifswald group will likely foster additional studies. The emerging insights support the notion of a tailored B cell response during normally progressing pregnancies, which endows B cell subsets to promote fetal tolerance and concomitantly maintain maternal immunity (Fig. 1) . The next milestones that need to be addressed include the clear-cut identification of the purpose of the observed B cell changes during pregnancy, for example by experimentally addressing their role in maintaining maternal immunity. In this context, the identification of an interaction between B cells and other leukocytes of the innate and adaptive arms of immune system, as well as pregnancy-related hormones, will also be critical. Furthermore, considering that B cell subsets can be functionally promiscuous, future research is needed to assess if pregnancy complications such as spontaneous abortion, preeclampsia, or intrauterine growth restriction are caused or aggravated by the failure to mount a tailored B cell response. Insights obtained from B cell-related research endeavors addressing these issues in the future may open exciting avenues for therapeutic B cell-targeted interventions during high-risk pregnancies, aiming to improve maternal and children's health. Because the development of new therapeutic approaches to treat pregnancy complications is severely restricted, pilot data are likely continue to emerge from observations on pregnancy outcomes in female patients treated with therapies that target B cells, such as rituximab, a monoclonal antibody directed against the B cell surface antigen CD20 [24] . ARCK ET AL.
